We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Taiwan, Johnson & Johnson, Palantir, Title and Altigen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 17, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Taiwan Semiconductor Manufacturing Co. Ltd. (TSM - Free Report) , Johnson & Johnson (JNJ - Free Report) , Palantir Technologies Inc. (PLTR - Free Report) and Title Company (ITIC - Free Report) and Altigen Communications, Inc. (ATGN - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Taiwan Semi, Johnson & Johnson and Palantir
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Taiwan Semiconductor Manufacturing Co. Ltd., Johnson & Johnson and Palantir Technologies Inc., as well as two micro-cap stocks Investors Title Company and Altigen Communications, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Taiwan Semiconductor’s shares were in line with the Zacks Semiconductor - Circuit Foundry industry over the year-to-date period (+32% vs. +32%). The company benefits from rising demand for AI computing and a process roadmap that brings customers to successive technology generations. Its design ecosystem and advanced packaging services deepen customer relationships, while manufacturing scale and cash generation support continued investment.
Overseas capacity adds geographic choice for customers but carries lasting cost disadvantages. Heavy capital commitments and recurring new-process ramp costs can limit how much revenue growth converts into shareholder cash returns.
Customer concentration, supply bottlenecks and uneven consumer demand also constrain the breadth of growth. Currency exposure, export licensing, and a production base concentrated in Taiwan leave earnings sensitive to factors beyond chip adoption, even as productivity efforts partially offset them.
Shares of Johnson & Johnson have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+40.3% vs. +29.1%). The company’s Innovative Medicines unit is its primary growth engine despite Stelara LOE, driven by key products like Darzalex, Tremfya and Erleada and new drugs, Spravato, Carvykti and Tecvayli. J&J has also rapidly advanced its pipeline in the past year that will help drive growth through the back half of the decade.
The company has “line of sight” to double-digit top-line growth by the end of the decade. However, J&J’s MedTech growth remains constrained by weaker Abiomed demand, China’s volume-based procurement and electrophysiology competition.
J&J also faces pressure from Stelara’s LOE and rising generic/biosimilar competition across several drugs. The talc litigation also remains a financial overhang, with the proposed settlement still conditional.
Palantir’s shares have underperformed the Zacks Internet - Software industry over the year-to-date period (-5.5% vs. -2%). The company is facing intense competition from larger rivals, rising technical expenses and fixed cloud commitments could pressure margins and constrain cost flexibility. Concentrated receivables pose cash flow risks, while the absence of dividends limits its appeal to income-focused investors.
These risks temper growth prospects, supporting a Neutral recommendation on PLTR. Nevertheless, PLTR’s share pieces reflecting optimism surrounding its AI-driven growth prospects.
Rising adoption of its AI platforms across government and commercial markets, expanding customer relationships and strong cash generation support sustained growth. Its land-and-expand strategy and ample liquidity provide flexibility to fund innovation, product development and technical hiring.
Shares of Investors Title have gained +4.5% over the year-to-date period against the Zacks Insurance - Property and Casualty industry’s gain of +16.3%. This microcap company with a market capitalization of $480.47 million sees its premium growth supported by higher real estate transaction volumes, geographic expansion and favorable net title insurance rate changes. Third-quarter 2026 net premiums written rose 20.9%, while its sizable investment portfolio and sound liquidity provide resilience.
The board also declared a $19.27-per-share special dividend alongside its regular quarterly payout. However, claims provisions and agent commissions rose sharply, contributing to a decline in third-quarter earnings and margins.
Weakness in like-kind exchange activity limits diversification, and the title business remains sensitive to housing conditions and concentrated regional markets. These offsetting factors temper the outlook despite continued premium momentum, substantial capital resources and long-term expansion opportunities.
Altigen Communications’ shares have gained +1% over the year-to-date period against the Zacks Communication - Components industry’s gain of +38.1%. This microcap company with a market capitalization of $11.13 million, has seen its cloud transition gaining momentum as new cloud revenues have begun exceeding legacy churn, supported by its largest-ever cloud customer, larger enterprise wins and an expanding AI portfolio.
CoreInteract, CoreEngage and CoreInsights broaden its addressable market and create cross-selling opportunities, while the Fiserv relationship offers a scalable channel into financial services. Its installed MAXCloud and MaxCS base also provides a lower-friction path for cloud migrations and AI adoption.
However, the company's fiscal third-quarter revenues fell 14.2%, margins compressed, and customer concentration remained high at 74% for the top five customers and resellers. Rising development spending and impairment risk add uncertainty. At 0.61X EV/sales, valuation remains below industry levels and historical medians.
Image: Bigstock
The Zacks Analyst Blog Highlights Taiwan, Johnson & Johnson, Palantir, Title and Altigen
For Immediate Release
Chicago, IL – November 17, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Taiwan Semiconductor Manufacturing Co. Ltd. (TSM - Free Report) , Johnson & Johnson (JNJ - Free Report) , Palantir Technologies Inc. (PLTR - Free Report) and Title Company (ITIC - Free Report) and Altigen Communications, Inc. (ATGN - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Taiwan Semi, Johnson & Johnson and Palantir
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Taiwan Semiconductor Manufacturing Co. Ltd., Johnson & Johnson and Palantir Technologies Inc., as well as two micro-cap stocks Investors Title Company and Altigen Communications, Inc.The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Taiwan Semiconductor’s shares were in line with the Zacks Semiconductor - Circuit Foundry industry over the year-to-date period (+32% vs. +32%). The company benefits from rising demand for AI computing and a process roadmap that brings customers to successive technology generations. Its design ecosystem and advanced packaging services deepen customer relationships, while manufacturing scale and cash generation support continued investment.
Overseas capacity adds geographic choice for customers but carries lasting cost disadvantages. Heavy capital commitments and recurring new-process ramp costs can limit how much revenue growth converts into shareholder cash returns.
Customer concentration, supply bottlenecks and uneven consumer demand also constrain the breadth of growth. Currency exposure, export licensing, and a production base concentrated in Taiwan leave earnings sensitive to factors beyond chip adoption, even as productivity efforts partially offset them.
(You can read the full research report on Taiwan Semiconductor here >>>)
Shares of Johnson & Johnson have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+40.3% vs. +29.1%). The company’s Innovative Medicines unit is its primary growth engine despite Stelara LOE, driven by key products like Darzalex, Tremfya and Erleada and new drugs, Spravato, Carvykti and Tecvayli. J&J has also rapidly advanced its pipeline in the past year that will help drive growth through the back half of the decade.
The company has “line of sight” to double-digit top-line growth by the end of the decade. However, J&J’s MedTech growth remains constrained by weaker Abiomed demand, China’s volume-based procurement and electrophysiology competition.
J&J also faces pressure from Stelara’s LOE and rising generic/biosimilar competition across several drugs. The talc litigation also remains a financial overhang, with the proposed settlement still conditional.
(You can read the full research report on Johnson & Johnson here >>>)
Palantir’s shares have underperformed the Zacks Internet - Software industry over the year-to-date period (-5.5% vs. -2%). The company is facing intense competition from larger rivals, rising technical expenses and fixed cloud commitments could pressure margins and constrain cost flexibility. Concentrated receivables pose cash flow risks, while the absence of dividends limits its appeal to income-focused investors.
These risks temper growth prospects, supporting a Neutral recommendation on PLTR. Nevertheless, PLTR’s share pieces reflecting optimism surrounding its AI-driven growth prospects.
Rising adoption of its AI platforms across government and commercial markets, expanding customer relationships and strong cash generation support sustained growth. Its land-and-expand strategy and ample liquidity provide flexibility to fund innovation, product development and technical hiring.
(You can read the full research report on Palantir here >>>)
Shares of Investors Title have gained +4.5% over the year-to-date period against the Zacks Insurance - Property and Casualty industry’s gain of +16.3%. This microcap company with a market capitalization of $480.47 million sees its premium growth supported by higher real estate transaction volumes, geographic expansion and favorable net title insurance rate changes. Third-quarter 2026 net premiums written rose 20.9%, while its sizable investment portfolio and sound liquidity provide resilience.
The board also declared a $19.27-per-share special dividend alongside its regular quarterly payout. However, claims provisions and agent commissions rose sharply, contributing to a decline in third-quarter earnings and margins.
Weakness in like-kind exchange activity limits diversification, and the title business remains sensitive to housing conditions and concentrated regional markets. These offsetting factors temper the outlook despite continued premium momentum, substantial capital resources and long-term expansion opportunities.
(You can read the full research report on Investors Title here >>>)
Altigen Communications’ shares have gained +1% over the year-to-date period against the Zacks Communication - Components industry’s gain of +38.1%. This microcap company with a market capitalization of $11.13 million, has seen its cloud transition gaining momentum as new cloud revenues have begun exceeding legacy churn, supported by its largest-ever cloud customer, larger enterprise wins and an expanding AI portfolio.
CoreInteract, CoreEngage and CoreInsights broaden its addressable market and create cross-selling opportunities, while the Fiserv relationship offers a scalable channel into financial services. Its installed MAXCloud and MaxCS base also provides a lower-friction path for cloud migrations and AI adoption.
However, the company's fiscal third-quarter revenues fell 14.2%, margins compressed, and customer concentration remained high at 74% for the top five customers and resellers. Rising development spending and impairment risk add uncertainty. At 0.61X EV/sales, valuation remains below industry levels and historical medians.
(You can read the full research report on Altigen Communications here >>>)